Filing Details
- Accession Number:
- 0000950170-24-073851
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-14 18:02:51
- Reporting Period:
- 2024-06-14
- Accepted Time:
- 2024-06-14 18:02:51
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
906709 | Nektar Therapeutics | NKTR | Pharmaceutical Preparations (2834) | 943134940 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1227886 | Robert Chess | C/O Nektar Therapeutics 455 Mission Bay Blvd South San Francisco CA 94158 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-06-14 | 19,500 | $1.20 | 255,273 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 2,100 | Indirect | by daughter |
Common Stock | 2,100 | Indirect | by son |
Common Stock | 2,100 | Indirect | by daughter |
Footnotes
- This transaction was made pursuant to a Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades at prices ranging from $1.19 to $1.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
- The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.